van Laar JA. Expanding treatment options by selectively targeting the cytokine storm with ruxolitinib in primary hemophagocytic lymphohistiocytosis. haematol [Internet]. 2024Feb.1 [cited 2024Oct.6];109(2):374-5. Available from: https://haematologica.org/article/view/haematol.2023.283915